培美曲塞联合卡铂治疗晚期非鳞非小细胞肺癌的疗效观察  

Clinical observation of pemetrexed and carboplatin in patients with advanced non-squamous nonsmall cell lung cancer

作　　者：周向毅[1] 周婷[1] 邱晶[1] 

机构地区：[1]江苏省镇江市解放军第三五九医院肿瘤肝病科,镇江212001

出　　处：《中国肿瘤临床与康复》2013年第8期896-898,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨培美曲塞联合卡铂治疗晚期非鳞非小细胞肺癌的临床疗效。方法选择收治的104例晚期非鳞非小细胞肺癌患者,随机分为观察组(52例)和对照组(52例)。观察组患者采用培美曲塞联合卡铂治疗,对照组患者采用吉西他滨联合卡铂治疗,比较两组患者的治疗效果。结果治疗后,观察组患者有效率为46.2%,对照组为44.7%,差异无统计学意义(2=1.25,P>0.05),观察组患者不良反应发生率明显低于对照组患者,差异均有统计学意义(均P<0.05),观察组患者的疾病进展时间(TTP)、中位生存时间(MST)和1年生存率分别为(6.2±2.1)个月、(8.9±2.1)个月和51.8%,均明显优于对照组患者,差异均有统计学意义(均P<0.05)。结论培美曲塞联合卡铂治疗晚期非鳞非小细胞肺癌疗效显著,提高了患者生活质量,值得临床推广。Objective To investigate the clinical efficacy of pemetrexed plus carboplatin in patients with advanced non-squamous non-small cell lung cancer.Methods In our hospital 104 cases of advanced non-squamous non-small cell lung cancer patients were divided into two groups,including the observation group of 52 cases were treated with pemetrexed plus carboplatin,while the control group of 52 patients was treated with gemcitabine and carboplatins.Results After treatment,the effective rate of observation group of patients was 46.2%,the control group was 44.7%,there was no significant difference between the two groups（2= 1.25,P 0.05）,the incidence of adverse reactions of the observation group were significantly lower than control group of patients,and the differences were statistically significant（P 0.05）,the observation group patients TTP,MST and one year survival rate were（6.2 ± 2.1） months,（8.9 ± 2.1） months and 51.8%,were significantly better than the control group of patients,the differences were statistically significant（P 0.05）.Conclusions Pemetrexed plus carboplatin in patients with advanced nonsquamous non-small cell lung cancer has a very significant effect,thus greatly improving the patient＇s quality of life,and it is worthy of promotion.

关 键 词：培美曲塞 卡铂 晚期非鳞非小细胞肺肿瘤 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]